PART 2
For three months, I went entirely dark.
I settled into my new apartment in downtown Chicago, changed my personal cell number, and assumed technical leadership of the federal tissue regeneration program. For the first time in my career, my work came with a clear employment contract, a competitive salary, an elite research team, and my name listed explicitly as Lead Principal Investigator.
My time at Vance Biomedical had been entirely different.
My father had begged for my “temporary help” right after I finished my Ph.D. That temporary help turned into late nights, weekends, and years of drafting clinical protocols, correcting failed experiments, and preparing FDA filings without ever receiving a formal corporate title or equity. Whenever I brought up an official employment contract, my father would offer the same dismissive brush-off:
“We’re family, Evelyn. Don’t make things complicated.”
Because he insisted on keeping things informal, I never signed an Intellectual Property Assignment Agreement. And as a precaution, I had archived every original dataset, timestamped email, and lab notebook on my secure personal drive.
The first sign of trouble reached me through the legal department at my new institution. The U.S. Patent and Trademark Office (USPTO) had issued severe rejection notices regarding four major patent applications recently filed by Vance Biomedical. The technical descriptions were riddled with gaps, critical chemical parameters were missing, and several experimental claims couldn’t be substantiated by the submitted data.
Without me, nobody at Vance Biomedical knew how to bridge the technical gaps.
Julian, whose private equity firm had backed my father’s recent expansion, had placed Chloe as the company’s new “Director of Clinical Development.” It sounded impressive on paper. The problem was that Chloe was excellent at repeating my high-level summaries at dinner parties, but she had no idea how the underlying science actually worked.
She could talk effortlessly about biomaterial matrices to investors. She couldn’t defend a complex patent claim against a senior USPTO examiner.
When Vance Biomedical hired an outside law firm to salvage the rejected applications, the attorneys discovered something far worse: the metadata across dozens of foundational files bore the name of the true author.
Evelyn Vance, Ph.D.
There was not a single executed contract showing that I had assigned those trade secrets or inventions to the company.
Julian began searching for me frantically. He called my former university colleagues. He emailed my old academic advisors. He tried tracing my whereabouts through mutual acquaintances. He hit a brick wall at every turn.
It was my brother, Arthur, who finally figured out where I had gone. He recalled me mentioning a federal grant initiative centered on advanced tissue scaffolds months ago.
That very evening, as I later learned, Julian rushed over to my parents’ house carrying a damning IP audit report.
“Marcus,” Julian demanded, slamming the file onto the kitchen island. “Tell me Evelyn signed the corporate IP assignment.”
My father sat in total silence. He didn’t have to say a word.